

Warsaw, 12.10.2022

**CeCert Sp. z o.o.**  
**ul. Warecka 11A**  
**00-034 Warszawa**

**Shenzhen Microprofit Biotech Co., Ltd.**  
**Rm. 405, 406, Zone B /4F, Rm. 205, 206-1**  
**207, West Side of Zone B/ 2F, Haowei**  
**Building, No. 8 Langshan 2nd Road**  
**Songpingshan, Songpingshan Community**  
**Xili Street, Nanshan District, Shenzhen**  
**P.R. China**

Ref: CeCert/337/2022

Dear Sirs,

With reference to the application 63B/2022 and 64A/2022 regarding the assessment of the documentations of an IVD medical devices for self-testing:

- fluorecare SARS-CoV-2 & Influenza A/B & RSV Antigen Combo Test Kit,
- fluorecare SARS-CoV-2 Antigen Test Kit (Saliva),

manufactured by Shenzhen Microprofit Biotech Co., Ltd. due to the change, I would like to inform that we have completed the assessment of the reported change with a positive result.

The multilingual IFUs and labels for both dVICES as well as the IFUs and labels with the new additional brand "SOLMIRA" have been approved.

EC certificates of conformity no. CeCert/091/W/E.1 and CeCert/092/W/E.2 remain in force and valid.

Sincerely,

**Director of in Vitro Diagnostic Medical  
Devices Certification Department**



NIP: 1231429092  
REGON: 382803094  
KRS: 0000776156



CeCert Sp. z o.o.  
ul. Warecka 11A  
00-034 Warszawa



Telefon: 721 721 526  
E-mail: [biuro@cecercert.pl](mailto:biuro@cecercert.pl)  
Web: [www.cecercert.pl](http://www.cecercert.pl)